CD8A and neoplasm: Here we show that, in parallel to their well-documented direct tumor killing capability49, Trm cells can activate cross-presenting dermal DCs, resulting in the subsequent priming and expansion of new CD8+ T cells specific to tumor-derived neo- and self-antigens.